FDA postpones decision on Intercept's lead liver drug

(Reuters) - The U.S. Food and Drug Administration has postponed by three months its decision on Intercept Pharmaceuticals Inc's marketing application for its lead drug, to treat a kind of liver disease.

http://ift.tt/1RrVfLP

from Reuters: Health News
via animenewspro